Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 June, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Jagsonpal Pharmaceuticals Ltd

About the Company - Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 226.10 Cr. and Equity Capital is Rs. 13.10 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsT-210 J, Shahpur Jat, New Delhi Delhi 110049cs@jagsonpal.com
http://www.jagsonpal.com
Management
NamePosition Held
Mr. Rajpal Singh KochharChairman Emeritus
Mr. Manish GuptaManaging Director
Mr. Harsha RaghavanChairman & Non-Exe.Director
Mr. Prithipal Singh KochharNon Executive Director
Mr. Debasis Bikash NandyIndependent Director
Ms. Radhika Madhukar DudhatIndependent Director
Ms. Pallavi Dinodia GuptaIndependent Director

Basic Stock Data of Jagsonpal Pharmaceuticals Ltd

Last Updated: June 25, 2024, 10:36 pm

Market Cap 900 Cr.
Current Price 340
High / Low515/270
Stock P/E40.1
Book Value 70.9
Dividend Yield1.47 %
ROCE17.0 %
ROE13.0 %
Face Value 5.00
PEG Ratio1.37

Competitors of Jagsonpal Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Aarey Drugs & Pharmaceuticals Ltd 121 Cr. 47.668.0/30.025.8 52.30.00 %4.44 %3.78 % 10.0
Pharmaids Pharmaceuticals Ltd 183 Cr. 52.079.2/30.0 20.40.00 %27.8 %16.9 % 10.0
Jubilant Pharmova Ltd 12,047 Cr. 756775/319295 3410.66 %6.74 %0.76 % 1.00
Amerise Biosciences Ltd 4.23 Cr. 0.640.93/0.54 0.810.00 %2.73 %2.75 % 1.00
RPG Life Sciences Ltd 2,522 Cr. 1,5251,740/87628.8 2271.05 %34.7 %25.7 % 8.00
Industry Average15,504.34 Cr1,228.8438.37197.530.34%17.32%16.75%6.52

Jagsonpal Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales57.1042.8454.0559.4954.4751.2360.6060.5360.1455.4560.1557.8347.25
Expenses50.6137.7244.7750.0948.8550.4553.4247.6251.5050.0151.5249.4643.85
Operating Profit6.495.129.289.405.620.787.1812.918.645.448.638.373.40
OPM %11.37%11.95%17.17%15.80%10.32%1.52%11.85%21.33%14.37%9.81%14.35%14.47%7.20%
Other Income0.532.660.820.281.950.37-3.151.121.742.562.002.272.52
Interest0.140.130.110.060.060.060.010.030.180.200.150.220.23
Depreciation0.270.260.280.230.370.650.190.200.330.480.390.460.41
Profit before tax6.617.399.719.397.140.443.8313.809.877.3210.099.965.28
Tax %17.85%30.85%29.45%30.24%24.23%31.82%23.50%24.49%21.07%23.50%25.87%25.00%24.81%
Net Profit5.435.106.856.565.410.312.9210.417.795.607.487.473.96
EPS in Rs2.071.952.612.502.070.121.113.972.972.142.862.851.51

Last Updated: May 6, 2024, 2:34 pm

Jagsonpal Pharmaceuticals Ltd Quarterly Chart

Jagsonpal Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales177166144138143144127167159188218237234
Expenses160156133129132138138157150169192202202
Operating Profit1710119126-119919263531
OPM %9%6%7%6%8%4%-9%6%5%10%12%15%13%
Other Income00001130134329
Interest4554531111001
Depreciation3333320111212
Profit before tax10332414-129922273537
Tax %26%28%16%30%20%18%1%20%16%22%29%23%
Net Profit7221312-127817192728
EPS in Rs2.850.700.810.451.244.53-4.412.763.006.517.2010.2010.82
Dividend Payout %18%72%62%22%8%2%-2%9%17%15%56%49%

Jagsonpal Pharmaceuticals Ltd Profit & Loss Yearly Chart

Jagsonpal Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:4%
5 Years:5%
3 Years:4%
TTM:-12%
Compounded Profit Growth
10 Years:27%
5 Years:25%
3 Years:10%
TTM:-23%
Stock Price CAGR
10 Years:36%
5 Years:66%
3 Years:30%
1 Year:-8%
Return on Equity
10 Years:8%
5 Years:14%
3 Years:16%
Last Year:13%

Last Updated: June 25, 2024, 5:06 pm

Jagsonpal Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313131313131313131313
Reserves858585828597859198109120146156
Borrowings353336393888457069
Other Liabilities23212219222523283135313031
Total Liabilities156153156154159143130136147164164195209
Fixed Assets59585652522221222226232410
CWIP1220003440000
Investments0000000011155111
Other Assets96929810210812110511010912391170198
Total Assets156153156154159143130136147164164195209

Jagsonpal Pharmaceuticals Ltd Reserves and Borrowings Chart

Jagsonpal Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 712849-3-2311128747
Cash from Investing Activity -5-3-1-0-241-3-1-11-2-26-58
Cash from Financing Activity 0-8-4-1-6-34-1-6-1-7-18-0
Net Cash Flow302215-624-019-36-11

Jagsonpal Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days9311511910610073454925263219
Inventory Days1271731762462953071641911341228168
Days Payable282942605654597682766435
Cash Conversion Cycle19225925229233932515016477724953
Working Capital Days130155171169174173766645593659
ROCE %6%6%5%7%3%-10%9%9%18%20%26%

Jagsonpal Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Jagsonpal Pharmaceuticals Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters70.34%70.34%70.34%68.71%68.71%68.72%68.72%68.72%68.72%68.72%68.48%68.09%
FIIs0.00%0.11%0.20%0.00%0.00%0.13%0.11%0.10%0.37%0.38%0.53%0.73%
DIIs0.00%0.01%0.00%0.67%0.68%0.28%0.77%0.82%0.82%0.82%0.82%0.84%
Public29.65%29.54%29.46%30.61%30.61%30.85%30.40%30.34%30.07%30.07%30.16%30.33%
No. of Shareholders14,65514,35320,03117,10016,19414,95214,53514,08413,78216,04115,78516,282

Jagsonpal Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Jagsonpal Pharmaceuticals Ltd Shareholders

Jagsonpal Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF830.040832024-06-200%

Jagsonpal Pharmaceuticals Ltd ROCE Trend

Jagsonpal Pharmaceuticals Ltd EPS Trend

Jagsonpal Pharmaceuticals Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue5.005.005.005.005.00
Basic EPS (Rs.)8.4910.207.486.513.00
Diluted EPS (Rs.)8.4610.207.486.513.00
Cash EPS (Rs.)9.1310.668.066.713.44
Book Value[Excl.RevalReserv]/Share (Rs.)70.8860.6546.9643.5539.39
Book Value[Incl.RevalReserv]/Share (Rs.)70.8860.6549.9546.5442.38
Dividend / Share (Rs.)5.005.004.001.000.50
Revenue From Operations / Share (Rs.)78.9490.3686.3071.7460.53
PBDIT / Share (Rs.)12.2315.2211.128.964.22
PBIT / Share (Rs.)11.6114.7610.548.763.79
PBT / Share (Rs.)11.3013.2910.438.353.59
Net Profit / Share (Rs.)8.5010.207.486.513.00
PBDIT Margin (%)15.4916.8412.8812.486.97
PBIT Margin (%)14.7016.3412.2012.216.26
PBT Margin (%)14.3114.7012.0811.635.93
Net Profit Margin (%)10.7611.288.669.074.96
Return on Networth / Equity (%)11.9816.8115.9214.957.62
Return on Capital Employeed (%)15.5023.1020.5518.548.69
Return On Assets (%)10.3413.7011.6210.385.35
Total Debt / Equity (X)0.000.000.000.050.04
Asset Turnover Ratio (%)1.011.301.361.211.12
Current Ratio (X)10.425.973.242.982.89
Quick Ratio (X)9.635.222.372.252.00
Inventory Turnover Ratio (X)1.241.241.361.311.19
Dividend Payout Ratio (NP) (%)0.000.0053.5015.3516.64
Dividend Payout Ratio (CP) (%)0.000.0049.6314.9114.55
Earning Retention Ratio (%)0.000.0046.5084.6583.36
Cash Earning Retention Ratio (%)0.000.0050.3785.0985.45
Interest Coverage Ratio (X)39.7496.57102.1821.6121.51
Interest Coverage Ratio (Post Tax) (X)28.6074.0869.7016.7116.31
Enterprise Value (Cr.)591.93644.85795.42154.9612.31
EV / Net Operating Revenue (X)2.842.723.520.820.07
EV / EBITDA (X)18.3016.1727.316.601.11
MarketCap / Net Operating Revenue (X)3.543.213.631.110.28
Retention Ratios (%)0.000.0046.4984.6483.35
Price / BV (X)3.954.786.681.830.44
Price / Net Operating Revenue (X)3.543.213.631.110.28
EarningsYield0.030.030.020.080.17

Jagsonpal Pharmaceuticals Ltd Profitability Ratios (%)

Jagsonpal Pharmaceuticals Ltd Liquidity Ratios

Jagsonpal Pharmaceuticals Ltd Liquidity Ratios (%)

Jagsonpal Pharmaceuticals Ltd Interest Coverage Ratios (%)

Jagsonpal Pharmaceuticals Ltd Valuation Ratios

Fair Value

Fair Value: 375.03

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 10.30% compared to the current price 340

Intrinsic Value: 484.72

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 42.57% compared to the current price ₹340

Last 5 Year EPS CAGR: 29.25%

*Investments are subject to market risks

Strength and Weakness of Jagsonpal Pharmaceuticals Ltd Stock

StrengthWeakness
  1. The company has higher reserves (101.85 cr) compared to borrowings (17.54 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (172.46 cr) and profit (12.54 cr) over the years.
  1. The stock has a low average ROCE of 8.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 109.42, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 185.33, which may not be favorable.

FAQ

What is the latest fair value of Jagsonpal Pharmaceuticals Ltd?

The latest fair value of Jagsonpal Pharmaceuticals Ltd is ₹375.03.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

The Market Cap of Jagsonpal Pharmaceuticals Ltd is 900 Cr..

What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 25 June 2024?

The current stock price of Jagsonpal Pharmaceuticals Ltd as on 25 June 2024 is ₹340.

What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is 515/270.

What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?

The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 40.1.

What is the Book Value of Jagsonpal Pharmaceuticals Ltd?

The Book Value of Jagsonpal Pharmaceuticals Ltd is 70.9.

What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?

The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 1.47 %.

What is the ROCE of Jagsonpal Pharmaceuticals Ltd?

The ROCE of Jagsonpal Pharmaceuticals Ltd is 17.0 %.

What is the ROE of Jagsonpal Pharmaceuticals Ltd?

The ROE of Jagsonpal Pharmaceuticals Ltd is 13.0 %.

What is the Face Value of Jagsonpal Pharmaceuticals Ltd?

The Face Value of Jagsonpal Pharmaceuticals Ltd is 5.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jagsonpal Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE